Acute lead-induced vasoconstriction in the vascular beds of isolated perfused rat tails is endothelium-dependent

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 5, 2010, Pages 492-499

  Silveira, E A ^a   Lizardo, J H F ^a   Souza, L P ^a   Stefanon, I ^a   Vassallo, D V ^a,b  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

Author keywords

Endothelium; Hypertension; Lead acetate; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; LEAD ACETATE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY PERFUSION; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; MALE; MUSCLE RELAXATION; NONHUMAN; RAT; SENSITIVITY ANALYSIS; TAIL ARTERY; TOXICITY TESTING; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 77952894260     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500027     Document Type: Article

References (39)

1. Bhatnagar A. Cardiovascular pathophysiology of environmental pollutants. Am J Physiol Heart Circ Physiol 2004; 286: H479-H485.
2. Agency for toxic substances and disease registry (ATSDR): Toxicological profile for lead. US Department of Health and Human Services, Public Health Service, 1993, Atlanta.
3. Sharifi MA, Darabi R, Akbarloo N, Larijani B, Khoshbaten A. Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension. Toxicol Lett 2004; 153: 233-238.
4. Moller L, Kristensen TS. Blood lead as a cardiovascular risk factor. Am J Epidemiol 1992; 136: 1091-1100.
5. Maheswaran R, Gill JS, Beevers DG. Blood pressure and industrial lead exposure. Am J Epidemiol 1993; 137: 645-653.
6. Levin SM, Goldberg M. Clinical evaluation and management of lead-exposure construction workers. Am J Ind Med 2000; 37: 23-43.
7. Barbosa F Jr, Sertorio JTC, Gerlach RF, Tanus-Santos JE. Clinical evidence for lead-induced inhibition of nitric oxide formation. Arch Toxicol 2006; 80: 811-816.
8. Kopp SJ, Baker JC, D'Agrosa LS, Hawley PL. Simultaneous recording of His bundle electrogram, electrocardiogram, and systolic tension from intact modified Langendorff rat heart preparations, I: Effects of perfusion time, cadmium, and lead. Environ Health Perspect 1978; 46: 475-487.
9. Prentice RC, Kopp SJ. Cardiotoxicity of lead at various perfusate calcium concentrations: Functional and metabolic responses of the perfused rat heart. Toxicol Appl Pharmacol 1985; 81: 491-501.
10. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999; 56: 1492-1498.
11. Weiler E, Khalil-Manesh F, Gonick H. Effects of lead and natriuretic hormone on kinetics of sodium-potassium-activated adenosine triphosphatase: Possible relevance to hypertension. Environ Health Perspect 1988; 78: 113-115.
12. Rosenblum WI. Effects of lead and other cations on pial arteries of the mouse. Acta Neuropathol 1965; 5: 54-60.
13. Piccinini F, Favalli L, Chiari MC. Experimental investigations on the contraction induced by lead in arterial smooth muscle. Toxicology 1977; 8: 43-51.
14. Webb RC, Winquist RJ, Victery W, Vander AJ. In vivo and in vitro effects of lead on vascular reactivity in rats. Am J Physiol 1981; 241: H211-H216
15. Lyn Patrick ND. Lead toxicity part II: The role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altern Med Rev 2006; 11: 114-127
16. Tsao D-A, Yu H-S, Cheng J-T, Ho C-K, Chang H-R. The change of β-adrenergic system in lead-induced hypertension. Toxicol Appl Pharmacol 2000; 163: 127-133.
17. Stöfen D. Environmental lead and the heart. J Mol Cell Cardiol 1974; 6: 285-290.
18. Hejtmancik MR, Williams BJ. Effects of chronic lead exposure on the direct and indirect components of the cardiac response to norepinephrine. Toxicol Appl Pharmacol 1979; 51: 239-245.
19. Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy RE. Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens 1993; 6: 723-729.
20. Skoczynska A, Stojek E, Gorecka H, Wojakowska A. Serum vasoactive agents in lead-treated rats. Int J Occup Med Environ Health 2003; 16: 169-177.
21. Vaziri ND, Ding Y, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in leadinduced hypertension: effects of lazaroid therapy. Kidney Int 1997; 52: 1042-1046.
22. França AS, Rossoni LV, Amaral SMC, Vassallo DV. Reactivity of the isolated perfused rat tail vascular bed. Braz J Med Biol Res 1997; 30: 891-895.
23. Vassallo DV, Lebarch EC, Moreira CM, Wiggers GA, Stefanon I. Lead reduces tension development and the myosin ATPase activity on the right ventricular myocardium. Braz J Med Biol Res 2008; 41: 789-795.
24. Rossoni LV, Cunha V, França A, Vassallo DV. The influence of nanomolar ouabain on vascular pressor responses is modulated by the endothelium. J Cardiovasc Pharmacol 1999; 34: 887-892.
25. Rossoni LV, Salaices M, Miguel M, Briones AM, Barker LA, Vassallo DV, et al. Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ 2002; 283: H2110-H2118.
26. Oishi H, Nakashima M, Totoki T, Tomokuni K. Chronic lead exposure may inhibit endothelium-dependent hyperpolarizing factor in rats. J Cardiovasc Pharmacol 1996; 28: 558-563
27. Mittal CK, Harrell WB, Mehta CS. Interaction of heavy metal toxicants with brain constitutive nitric oxide synthase. Mol Cell Biochem 1995; 149/150: 263-265.
28. Chai S, Webb RC. Effects of lead on vascular reactivity. Environ Health Perspect 1988; 78: 85-89.
29. Watts SW, Chai S, Webb RC. Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C. Toxicology 1995; 99: 55-65.
30. Heydari A, Norouzzadeh A, Khoshbaten A, Asgari A, Ghasemi A, Najafi S, et al. Effects of short term and subchronic lead poisoning on nitric oxide metabolites and vascular responsiveness in rat. Toxicol Lett 2006; 6: 180-189.
31. Carmignani M, Volpe AR, Boscollo P, Qiao N, Di Gioacchino M, Grilli A, et al. Catecholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 2000; 68: 401-415.
32. Marques M, Millás I, Jiménez A, García-Colis E, Rodriguez-Feo J, Velasco S, et al. Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 2001; 12: 2594-2600.
33. Courtois E, Marques M, Barrientos A, Casado S, López-Farré A. Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J Am Soc Nephrol 2003; 14: 1464-1470.
34. Nakamura T, Sakamoto K. Reactive oxygen species upregulates cyclooxygenase-2, p53 and Bax mRNA expression in bovine luteal cells. Biochem Biophys Res Commun 2001; 284: 203-210.
35. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND. Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species. Hypertension 1997; 30: 1487-1492.
36. Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 2004; 66: 2329-2336
37. Harlan WR. The relationship of blood lead levels to blood pressure in the U.S. population. Environ Health Perspect 1988; 78: 9-13.
38. Navas-Ancien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease A systematic review. Environ Health Perspect 2007; 115: 472-482.
39. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 2002; 162: 2443-2449.